[pending] IBUPROFEN (IBUPROFEN)
Pending LLM rewrite. Source: FDA_DRUG D-0390-2026.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
Presence of foreign substance: the firm received complaints for a gel-like mass and black particles in the product.
The recalled product
- Product
- IBUPROFEN (IBUPROFEN)
- Brand
- IBUPROFEN
- Manufacturer
- STRIDES PHARMA INC
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot: 7261973A
- 7261974A
- Exp 01/31/2027
UPCs (1)
- 0351672532185
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · IBUPROFEN
- HighIbuprofen tablets recalled nationwide due to temperature abuse during manufacturing
FDA (Drugs) · 2022-06-15
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27